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Pemoline, [(RS)-2-amino-5-phenyl-1,3-oxazol-4(5H)-one] 
is a central nervous system stimulant used to treat 
attention-deficit hyperactivity disorder (ADHD) and 
narcolepsy in humans (Molina and others 1981). In horse 
racing, pemoline is classified as an Association of Racing 
Commissioners International (ARCI) ‘Class 1’ foreign 
substance, i.e., an agent with high potential to influence 
performance (Tobin 1981 and ARCI website). Pemoline 
is unusually identified in a post-race sample, and its 
identification would usually be interpreted as an attempt 
to improperly influence performance. However, an entirely 
innocent explanation is possible for such pemoline 
identifications, as we will now set forth. 
The explanation is based on the fact that in the horse, 
and possibly other species, pemoline is a metabolite of 
levamisole, an anthelmintic and immune stimulant not 
uncommonly administered to horses (Mohri and others 
2005). The recommended dose in the horse is 2/mg/
kg orally, once a day for three-to-five days, as an immune 
modulator (Britt and Byars, 1997). Furthermore, in the 
horse levamisole, metabolism has recently been shown 
to produce a closely related substance, aminorex (Barker 
2008, Ho and others 2009, Pellegrini, 2010). Aminorex, 
which is structurally related to levamisole and pemoline 
(Figure 1), is a central nervous system stimulant which 
was marketed as a prescription anorectic in Europe, but 
withdrawn when it became associated with pulmonary 
hypertension (Gurtner 1985). In the United States, 
Aminorex is a DEA Schedule 1 substance and an ARCI 
‘Class 1’ substance, like pemoline.  
In the United States, the link between levamisole 
administration and aminorex identifications has been 
associated with a series of no fewer than 82 aminorex 
‘positives’ in post-race urines. These aminorex 
‘positives’ star ted with a single identification in Belgium, 
then, in the United States, first in October 2004 in 
Ohio, and later in both Pennsylvania and Ontario (Weber 
2010) as set for th in Table 1. In Pennsylvania, beginning 
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in October of 2005, testing indicated detections of 
aminorex in both blood and urine samples and by 
November 2006 aminorex ‘positives’ had been reported 
in all four Pennsylvania racetracks (Mushalko, 2010, 
Uboh, 2010). Each of these jurisdictions is a major 
North American racing jurisdiction, testing in the order 
of 15,000 samples per year or more at multiple racing 
venues, both Thoroughbred and Harness, in each 
jurisdiction.
Table 1: Time Sequence of Aminorex “positives” in North America, 2004-2009
State/Province 2004 2005 2006 2007 2008 2009 Total
Ohio 8 2 9 4 1 4 28
Pennsylvania 4 32 36
Ontario 18 18
Totals 8 6 41 22 1 4 82
As shown in Table  1, ‘positive’ reports for aminorex in the 
US and Canada peaked in 2006 with 41 total, followed by 
18 in 2007, principally in Ontario. It seemed unusual that 
these aminorex ‘positives’ continued to occur in the face 
of significant penalties against the horsemen involved: the 
penalty in Ohio usually being a fine of about $500, loss of 
purse and a six-month suspension.
The first direct association between these aminorex 
‘positives’ and levamisole administration was made by Dr 
Frank Pellegrini of Freedom Health, LLC, whose companies’ 
products had been linked to the aminorex identifications.  
Dr Pellegrini made the aminorex/levamisole association 
in about September 2006 when at least one of a group of 
horses that he had treated therapeutically with levamisole 
gave rise to an Ohio aminorex ‘positive’ (Tobin 2010).  
This finding led Dr Pellegrini and Freedom Health LLC 
to perform a carefully designed series of experimental 
administrations, using a number of different commercial 
levamisole sources, a number of selected Freedom 
Health products and two other non-levamisole wormers, 
Panacur and Safe-Guard. The post administration urine 
samples were then analyzed under contract by Industrial 
Laboratories in Denver, CO, and this work confirmed Dr 
Pellegrini’s proposed levamisole/aminorex relationship 
(Pellegrini 2010). The formal reporting of these findings 
on or about March 17th 2008 by Freedom Health, LLC, led 
to an abrupt decline in the number of aminorex ‘positive’ 
calls (Table 1). This levamisole to aminorex transformation 
was soon confirmed by the work of Dr Steve Barker of 
Louisiana State University (Barker 2008) and later by Ho 
and others (2009). 
About this time our group in Kentucky was researching 
the aminorex situation on behalf of Pennsylvania 
horsemen, and a proposed chemical levamisole/aminorex 
transformation mechanism was communicated by Dr 
Rodney Eisenberg of Frontier Biopharm to Dr Mike Weber 
in Ontario (Figure 1). In summary, work in 2006-2007 clearly 
established that aminorex is found in equine urine post 
levamisole administration and established a proposed 
chemical mechanism for these transformations. These 
findings led to forensic and regulatory re-evaluation of 
the significance of the aminorex ‘positives’ reported in a 
number of jurisdictions. 
Review of the data presented in Table 1 shows differing 
time courses of aminorex “positives” in each jurisdiction. 
Pennsylvania reported no aminorex “positives” after 2006, 
and eventually negotiated settlements with their horsemen. 
In Canada, there were no aminorex “positives” tested 
after 2007. On the other hand, Ohio continued testing 
aminorex ‘positives’ until at least 2009, apparently largely 
in Standardbred racing. Since drug testing continues at 
about the same rate in each of these North American 
racing jurisdictions, these changed positive call rates are 
presumably due to horsemen recognising levamisole as 
the source of many or most of these aminorex positives, 
and possibly also to regulatory re-evaluation of the 
forensic significance of very low concentration aminorex 
identifications. 
More recently, in October of 2009, we received a 
communication from a colleague of an English horse 
trainer who recently had two pemoline ‘positives’ and 
one apparently related tetramisole ‘positive’ called (Tobin 
2009). Responding to this request, we revisited the then 
well-established link between levamisole and aminorex, 
and reviewed the chemistry of levamisole, aminorex and 
pemoline. The structure of pemoline is closely related 
to that of aminorex, being a simple oxidation product of 
aminorex. It is therefore easy to extend the levamisole/
aminorex connection from levamisole, (the levo isomer 
of tetramisole, ergo the name levamisole) to aminorex 
and then, by simple oxidation, to pemoline. Im summary, 
any horse administered either levamisole or possibly 
tetramisole is at risk of producing either aminorex or 
pemoline positives, or, conceivably both, as set forth in 
this abbreviated chemical reaction scheme in Figure 1.  
Figure 1: Proposed conversion of Levamisole to Aminorex to Pemoline. 
Levamisole (1) can protonate to form intermediate 2, which can undergo 
alkylation of the double bond to form 3, with loss of thiirane, 3.1, to yield 
Aminorex 4. Aminorex can then undergo biological oxidation [O] to form 
Pemoline 5 (Eisenberg 2008; Ho, 2009).
Furthermore, pemoline has an unusually long (150 hour) 
apparent terminal half-life in horse urine and is thus likely 
to yield prolonged ‘detection times’ in post-race urine 
testing in horses, as shown by members of our research 
group 30 years ago (Tobin 1981). As such, it seems 
probable that one of the last metabolites to be detected 
after levamisole administration would be pemoline, as has 
apparently happened in the case of our English colleague, 
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and as has also apparently occurred previously in English 
racing (Tobin 2009).  
Consistent with this proposed mechanism, the horses 
involved in the recent English pemoline ‘positive’ had 
been administered levamisole on the recommendation of 
the trainer’s veterinarian. Levamisole was administered 
as a clear yellow solution containing 3% w/v Levamisole 
Hydrochloride Ph.Eur. Levacide 3% Drench, which is 
described as a broad spectrum anthelmintic for use in 
the treatment and control of nematode infections in cattle 
and sheep. at 2.5ml per 10kg of bodyweight (.http://www.
norbrook.co.uk/products/ProductPrintable.cfm/product_
Key/425/CatKey/1/Section/Veterinary_Products/).
Consistent with the above chemistry, two of these horses 
yielded positives for pemoline and a third horse was 
reported positive for Tetramisole, entirely consistent with 
the close structural relationship between levamisole and 
tetramisole. (Tobin 2009).
With respect to the matter of the regulatory outcome of this 
very unusual circumstance, we immediately communicated 
the results of our researches as outlined in this report to 
the trainer and veterinary surgeon involved. Additionally, 
we can report that these findings were of relevance 
to an enquiry held by the British Horseracing Authority 
Disciplinary Department, in that “the Panel was satisfied 
that the source of both pemoline and tetramisole was a 
five-day course of 120ml of Levacide for [horse #1] and 
[horse #2] and [horse #3] and a four-day course for [horse 
#4], which commenced on August 18, 2009 and was given 
under veterinary advice.” (http://www.britishhorseracing.
com/resources/about/whatwedo/disciplinary/
disciplinaryDetail.asp?item=091148)
In conclusion, administration of levamisole and presumably 
also tetramisole to horses which are likely to be medication 
tested should be avoided. This is because in the horse 
levamisole, and possibly also tetramisole can metabolise 
to two central nervous system stimulants, aminorex and 
pemoline, and as such have been associated with ‘positive’ 
calls for each of these substances in post-race urines. 
In point of fact, in the US, the link between levamisole 
administrations and aminorex identifications has led to 
the reclassification of levamisole, previously a substance 
of essentially no regulatory interest, as an ARCI class 
two agent (ARCI website). This is an explicit regulatory 
recognition of the ability of levamisole administration to 
produce aminorex ‘positives’ and now, based on these 
English reports, pemoline ‘positives’ in post-race urines. 
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